Clinical Trials

Clinical Trial Detail

Return to search results.

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

Complete title: Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution after Myeloablative Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV

Research Study Number       2212.00
    
Principal Investigator       Ann Woolfrey, MD
    
Phase       II

Look up trial at NIH

Research Study Description

This clinical trial studies the immune response after stem cell transplant in human immunodeficiency virus (HIV)-positive patients with hematologic cancer (blood cancer). Studying samples of blood from HIV-positive patients with cancer in the laboratory may help doctors learn more about changes that occur in the immune system after stem cell transplant.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: up to 75 Years

Genders Eligible for Study: Both

- Age < 66 years for autologous recipients; ages < 76 for allogeneic recipients

- HIV positive

- Treatment with highly active antiretroviral therapy (HAART) for at least 1 month

- Viral load has decreased by >= 1.5 logs or viral load < 5000 copies/ml plasma on HAART therapy

- Hematologic malignancy associated with a poor prognosis or other diagnosis for which hematopoietic cell therapy (allogeneic or autologous, including gene therapy) is indicated

- Approval for allogenic regimen given at Patient Care Conference

- DONOR: Autologous or allogeneic gene modified cells allowed

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- A medical history of noncompliance with HAART or medical therapy

- Inability to provide informed consent

- DONOR: Allogeneic donors must not have HIV infection

Other exclusion criteria may apply.



Research Study Number       2212.00
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Hematologic Malignancies; Immunodeficiency Syndromes

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials